Hepatocellular Carcinoma Clinical Trial
— SIRveNIBOfficial title:
Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Verified date | April 2018 |
Source | Singapore General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to assess the efficacy of SIRT as compared with
Sorafenib in patients with locally advanced liver cancer in terms of overall survival (OS).
The Study null hypothesis is, there is no difference in overall survival between patients
receiving SIRT and those receiving Sorafenib therapy.
Status | Active, not recruiting |
Enrollment | 360 |
Est. completion date | July 31, 2018 |
Est. primary completion date | July 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Disease must be locally advanced as defined by BCLC (B) intermediate stage or BCLC (C) advanced stage without extra-hepatic disease (only with branch portal vein thrombosis). - Willing, able and mentally competent to provide written informed consent prior to any testing undertaken for this study protocol, including screening tests and evaluations that are not considered to be part of the subject's routine care. - Aged 18 years/older (either gender). - Unequivocal diagnosis of HCC. - HCC not amenable to surgical resection or immediate liver transplantation, or cannot be optimally treated with local ablative techniques such as RFA, consistent with the practice of the clinical trial centre. - Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as = 10 mm with spiral CT scan or MRI. - ECOG performance status 0-1. - Child-Pugh A-B (up to 7 points) - Adequate haematological, renal and hepatic function as follows: - Leukocytes = 2,500/µL - Platelets = 80,000/µL - Haemoglobin > 9.5g/dL - Total bilirubin < 2.0mg/dL - INR = 2.0 - ALP = 5 x institutional ULN - AST and ALT = 5 x institutional ULN - Albumin = 2.5g/dL - Creatinine = 2.0mg/dL - Life expectancy of at least 3 months without any active treatment. - Suitable for protocol treatment as determined by clinical assessment undertaken by the Investigator. - Female patients must be either postmenopausal or, if premenopausal, must have a negative pregnancy test and agree to use 2 forms of contraception if sexually active during their study participation. - Male patients must be surgically sterile, or if sexually active and having a pre-menopausal female partner then must be using an acceptable form of contraception. Exclusion Criteria: - Have had more than 2 administrations of hepatic artery directed therapy. - Subjects who have had hepatic artery directed therapy done < 4 weeks prior to study entry. - Have had systemic chemotherapy for HCC except for prior adjuvant or neoadjuvant therapy given more than 6 months from enrolment. - have had prior treatment with Sorafenib or VEGF inhibitors. - Prior hepatic radiation therapy for HCC or other malignancy. - Currently receiving any other investigational agents for the treatment of their cancer. - Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other clinical signs of liver failure, on physical examination. - Complete main portal vein thrombosis. - Any metastatic disease (local-regional lymph nodes measuring less than 2 cm in greatest diameter or lung nodules measuring less than 1 cm are not contraindications as per Investigator discretion). - Any other concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 5 years. - Presence of clinical signs of CNS metastases due to their poor prognosis and because progressive neurologic dysfunction would confound the evaluation of neurologic and other adverse events. - Uncontrolled inter-current illness including, but not limited to, ongoing or active infection (except viral hepatitis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Any of the following contraindications to angiography and selective visceral catheterization: - Bleeding diathesis, not correctable by the standard forms of therapy. - Severe peripheral vascular disease that would preclude arterial catheterization. - Portal hypertension with hepato-fugal flow as documented on baseline spiral CT scan. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to SIR-Spheres or Sorafenib. - Inability or unwillingness to understand or sign a written informed consent document. - Female subjects who are pregnant or currently breastfeeding. - Female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as per Investigator discretion during the study. The rhythm method is not to be used as the sole method of contraception. - Male subjects, unwillingness to practice effective contraception (per Investigator discretion) while taking part in this study, because the effect of the SIR-Spheres treatment on sperm or upon the development of an unborn child are unknown. - Current enrolment in any other investigational therapeutic drug or device study. |
Country | Name | City | State |
---|---|---|---|
Brunei Darussalam | The Brunei Cancer Centre | Jerudong | Brunei |
China | Queen Mary Hospital | Hong Kong | Hong Kong |
Indonesia | University of Udayana, Rumah Sakit Sanglah, Indonesia | Denpasar | Bali |
Indonesia | Cipto Mangunkusumo Hospital ,University of Indonesia | Jakarta | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Korea University Anam Hospital | Seoul | |
Korea, Republic of | Seoul National University Bundang Hospital | Seoul | |
Korea, Republic of | Seoul St. Mary's Hospital | Seoul | |
Korea, Republic of | Severance Hospital, Yonsei University College of Medicine | Seoul | |
Malaysia | University Malaya Medical Center | Kuala Lumpur | |
Malaysia | Sarawak General Hospital | Kuching | Sarawak |
Malaysia | Penang Adventist Hospital | Penang | |
Mongolia | National Cancer Center of Mongolia | Ulaanbaatar | |
Myanmar | Yangon GI & Liver Centre | Yangon | |
New Zealand | Auckland City Hospital | Grafton | Auckland |
Philippines | Davao Doctors Hospital | Davao | |
Philippines | Makati Medical Center | Manila | Makati City |
Philippines | The Medical City | Pasig City | Manila |
Philippines | St. Luke's Medical Center, Philippines | Quezon City | Manila |
Singapore | Khoo Teck Puat Hospital | Singapore | |
Singapore | National Cancer Center Singapore | Singapore | |
Singapore | National University Hospital | Singapore | |
Singapore | Singapore General Hospital | Singapore | |
Taiwan | Kaohsiung Chang Gung Memorial Hospital | Kaohsiung | |
Taiwan | China Medical University Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei City | Taipei |
Taiwan | Taipei Veterans General Hospital | Taipei City | Taipei |
Taiwan | Chang Gung Memorial Hospital | Taoyuan | Taoyuan Hsien |
Thailand | Chulabhorn Hospital | Bangkok |
Lead Sponsor | Collaborator |
---|---|
Singapore General Hospital | National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore, Singapore Clinical Research Institute, Sirtex Medical |
Brunei Darussalam, China, Indonesia, Korea, Republic of, Malaysia, Mongolia, Myanmar, New Zealand, Philippines, Singapore, Taiwan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival | Overall Survival is defined as the time from the date of randomisation to the date of death due to any cause. All patients will be followed up until death to compare the overall survival between the two treatments. 2 years is an estimated time frame. | 2 years | |
Secondary | Progression free survival in the liver | Progression-free survival in the liver is defined as the time interval between randomisation and the date of tumour progression in the liver or death, whichever is earlier. Tumour progression in the liver will be determined from serial CT scans. Diagnosis of tumour progression of disease should be made using the RECIST guideline version 1.1. 2 years is an estimated time frame. | 2 years | |
Secondary | Progression free survival overall | Progression-free survival overall is defined as the time interval between randomisation and the date of tumour progression at any site in the body or death, whichever is earlier. Tumour progression at any site in the body will be measured by any definitive imaging technique including CT scan, MRI study or other nuclear medicine scan. The Investigator should clearly indicate the site of tumour progression (hepatic or extra-hepatic) at the time of recurrence. 2 years is an estimated time frame. |
2 years | |
Secondary | Tumour Response Rate | Tumour response and progression will be evaluated in this study using the new response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [European Journal of Cancer (45): 228 - 247, 2009] (http://ctep.cancer.gov/protocolDevelopment/docs/recist_guideline.pdf). 2 years is an estimated time frame |
2 years | |
Secondary | Toxicity and Safety | Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 4.02. Patients for both treatment arms will be followed-up for safety and toxicity from the time of study entry (randomisation day) until 30 days post study conclusion or until commencement of the next alternative therapy, which ever is earlier. | Up to 2 years | |
Secondary | Health Related Quality of Life (QoL) | Quality of life (QoL) will be measured by using the EQ-5D questionnaire over the study period. QoL for patients will be measured until their first disease progression up to 2 years (estimated) which ever is earlier. | Up to 2 years | |
Secondary | Liver resection rate | Patients will be assessed for suitability for liver resection every 12 weekly until their study conclusion up to 2 years which ever is earlier. | Up to 2 years | |
Secondary | Liver Transplantation Rate | Patients will be assessed for suitability for liver transplantation every 12 weekly until their study conclusion up to 2 years which ever is earlier. | Up to 2 years | |
Secondary | Time to Disease Progression | Time to Disease Progression (TTP) is defined as a measure of time after a disease is diagnosed (or treated) until the disease starts to get worse. Disease Progression will be measured by RECIST guideline version 1.1. TTP will be measured every 12 weekly up to 2 years (estimated). | Up to 2 years | |
Secondary | Disease control rate | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |